No Data
No Data
Shandong Buchang Pharmaceuticals (603858.SH): won the second prize of National Science and Technology Progress Award.
On June 24, 2024, the National Science and Technology Awards Conference for the year 2023 was held in Peking. Shandong Buchang Pharmaceuticals Co., Ltd., and Director Zhao Tao participated in the "key technology and application of research mode on classic prescription and formula compatibility Taboo rules and compatibility rules of traditional Chinese medicine" project, which won the second prize of the National Science and Technology Progress Award for 2023.
Even After Rising 4.2% This Past Week, Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Are Still Down 22% Over the Past Three Years
Shandong Buchang Pharmaceuticals (603858.SH) has cumulatively repurchased 2.01% of its shares, with a capital expenditure of 358 million yuan.
Shandong Buchang Pharmaceuticals (603858.SH) announced that as of June 17, 2024, the company has traded through centralized bidding...
Shandong Buchang Pharmaceuticals (603858.SH) plans to increase the amount of share repurchases to 360-720 million yuan.
Shandong Buchang Pharmaceuticals (603858.SH) has issued an announcement to promote the recognition of the company's future development and value based on confidence.
Shandong Buchang Pharmaceuticals (603858.SH) has cumulatively repurchased 1.97% of its shares, costing 351 million yuan.
Shandong Buchang Pharmaceuticals (603858. SH) announced that as of May 31, 2024, the company has repurchased a cumulative total of 21,787,500 shares through centralized bidding trading, accounting for 1.97% of the total share capital of the company. The highest price paid for the repurchased shares was 17.44 yuan/share, the lowest price paid was 14.16 yuan/share, and the total amount paid was 351 million yuan (excluding transaction fees).
Buchang Pharmaceutical (603858.SH): Holding subsidiary Qionglai Tianyin plans to increase capital and expand shares to implement equity incentives
Gelonghui, May 31, 丨 Buchang Pharmaceutical (603858.SH) announced that the company's holding subsidiary Qionglai Tianyin plans to implement equity incentives for Qionglai Tianyin's senior management and key employees in the form of capital increases and share expansion. The aforementioned incentive targets intend to participate in this equity incentive by directly holding shares in Qionglai Tianyin. The company agreed to relinquish priority payment rights. After the transaction was completed, the company's shareholding ratio in Qionglai Tianyin was changed from 92.75% to 91.3793%. The registered capital of Qionglai Tianyin increased from RMB 20 million to RMB 203 million. Qionglai Tianyin is still a holding subsidiary within the scope of the company's consolidated statements
No Data